McKesson (MCK) has been consistently highlighted as a strong value stock, with some investors heavily investing in the corporation, such as Avanza Fonder AB's $7.9 million investment. Predictably, this has resulted in McKesson outperforming its competitors on several strong trading days. However, the stock has also seen a significant decline post the divestiture of its Canada-based businesses including Rexall and Well.ca. This divestiture on one hand has contributed to a 15.2% drop in Q3, but on the other hand, it is part of McKesson's strategic shift to focus on Oncology and Biopharma growth. Meanwhile, McKesson's financial performance remains strong, with record revenue reported in its Q2 2025 earnings call. The corporation also continues to attract bullish speculation, with figures such as Jim Cramer endorsing McKesson as a potential buy. Furthermore, MCK has issued full year Earnings guidance for FY25 and notably beat quota in Q2, which suggests favourable outlook for the future.
Mckesson Corporation MCK News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sat, 18 Jan 2025 14:37:57 GMT -
Rating 7
- Innovation 4
- Information 6
- Rumor -2
